Figure 5. Hyperglycemia in Insr^P1195L/+/HFD mice is ameliorated by transplantation of wild-type subcutaneous WAT.

(a,b) Body weight (a) and blood glucose levels (b) (n = 13–15 per each group). (c) The blood glucose levels at 16-hr fasted and 3 hrs after food replenishment at 18–20 weeks of age (n = 7–10 per each group). (d,e) Western blot analysis of phospho-HSL levels in fasted and refed conditions. (d) A representative result showing increased phospho-HSL in Insr^P1195L/+/HFD mice. Endo., endogenous fat; Trans., transplanted fat. Cropped blots were used. Full-length blots are presented in Supplementary Fig. S6. (e) Quantified result of phospho-HSL levels. (n = 4 per each group). (f) mRNA expressions of G6pc in liver on fasted and refed conditions (nv6–8 per each group). (g) Serum adiponectin levels (n = 8 per each group). Data are mean ± SEM. Significance between treatment (un-transplanted Insr^P1195L/+/HFD and transplanted Insr^P1195L/+/HFD mice) at individual time points by two-tailed Student’s t-test (a–c,f). One-way ANOVA plus Bonferroni post-hoc analysis (e,g). *P < 0.05, **P < 0.01, ***P < 0.001, NS; not significant.